These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29737183)

  • 21. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study.
    Ronaldson KJ; Fitzgerald PB; Taylor AJ; Topliss DJ; Wolfe R; McNeil JJ
    Schizophr Res; 2012 Nov; 141(2-3):173-8. PubMed ID: 23010488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between electroencephalogram changes and plasma clozapine levels in clozapine-treated patients.
    Kim HS; Youn T; Kim SH; Jeong SH; Jung HY; Jeong SW; Kim KK; Kim YS; Chung IW
    Int Clin Psychopharmacol; 2019 May; 34(3):131-137. PubMed ID: 30855515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.
    Hummer M; Kemmler G; Kurz M; Kurzthaler I; Oberbauer H; Fleischhacker WW
    Am J Psychiatry; 1999 Apr; 156(4):631-3. PubMed ID: 10200746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.
    Brouwers EE; Söhne M; Kuipers S; van Gorp EC; Schellens JH; Koks CH; Beijnen JH; Huitema AD
    Clin Drug Investig; 2009; 29(1):59-63. PubMed ID: 19067475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.
    Centorrino F; Baldessarini RJ; Kando J; Frankenburg FR; Volpicelli SA; Puopolo PR; Flood JG
    Am J Psychiatry; 1994 Jan; 151(1):123-5. PubMed ID: 8267110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
    N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A drug-drug conditioning paradigm reveals multiple antipsychotic-nicotine interactions.
    Feng M; Sparkman NL; Sui N; Li M
    J Psychopharmacol; 2017 Apr; 31(4):474-486. PubMed ID: 28347260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pipamperone augmentation of clozapine and sodium valproate in refractory schizophrenia: a case report.
    Paraschakis A
    Clin Neuropharmacol; 2014; 37(2):60-1. PubMed ID: 24614672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight gain correlated with decrease in clozapine/N-desmethyl-clozapine ratio in a man with treatment-refractory schizophrenia.
    De Mel VN; Korman N; McArdle P; Siskind DJ
    Australas Psychiatry; 2018 Oct; 26(5):558-559. PubMed ID: 30269573
    [No Abstract]   [Full Text] [Related]  

  • 32. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
    Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
    Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
    Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
    Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report.
    De Berardis D; Campanella D; Serroni N; Rapini G; Olivieri L; Fornaro M; Valchera A; Iasevoli F; Napoletano C; Martinotti G; Giannantonio MD
    J Clin Psychopharmacol; 2014 Oct; 34(5):649-51. PubMed ID: 25006818
    [No Abstract]   [Full Text] [Related]  

  • 35. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
    Krakowski M; Czobor P; Citrome L
    Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
    Theisen FM; Haberhausen M; Firnges MA; Gregory P; Reinders JH; Remschmidt H; Hebebrand J; Antel J
    Pharmacogenomics J; 2007 Aug; 7(4):275-81. PubMed ID: 16983399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
    Šimić I; Potočnjak I; Kraljičković I; Stanić Benić M; Čegec I; Juričić Nahal D; Ganoci L; Božina N
    Pharmacogenomics; 2016 Aug; 17(13):1385-9. PubMed ID: 27469576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia.
    Menus Á; Kiss Á; Tóth K; Sirok D; Déri M; Fekete F; Csukly G; Monostory K
    Sci Rep; 2020 Dec; 10(1):21283. PubMed ID: 33277605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.
    Molina V; Gispert JD; Reig S; Sanz J; Pascau J; Santos A; Desco M; Palomo T
    Psychopharmacology (Berl); 2005 Feb; 178(1):17-26. PubMed ID: 15365682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.